Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment

Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment

Objectives: We aimed to assess safety, tolerability, and Plasmodium vivax relapse rates of ultra-short course (3.5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment. Methods: Childre...

Full description

Bibliographic Details
Main Authors: Sze-Ann Woon, Brioni R. Moore, Moses Laman, Paula Tesine, Lina Lorry, Bernadine Kasian, Phantica Yambo, Gumul Yadi, William Pomat, Kevin T. Batty, Sam Salman, Leanne J. Robinson, Timothy M.E. Davis, Laurens Manning
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:International Journal of Infectious Diseases
Subjects:
Plasmodium vivax
Pediatric
Primaquine
Plasmodium falciparum
Radical cure
Universal cure
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223000863

Internet

http://www.sciencedirect.com/science/article/pii/S1201971223000863

Similar Items